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Ullrich congenital muscular dystrophy (UCMD) is an autosomal recessive disorder characterized by generalized
muscular weakness, contractures of multiple joints, and distal hyperextensibility. Homozygous and compound
heterozygous mutations of COL6A2 on chromosome 21q22 have recently been shown to cause UCMD. We
performed a genomewide screening with microsatellite markers in a consanguineous family with three sibs affected
with UCMD. Linkage of the disease to chromosome 2q37 was found in this family and in two others. We analyzed
COL6A3, which encodes the a3 chain of collagen VI, and identified one homozygous mutation per family. In family
I, the three sibs carried an ArG transition in the splice-donor site of intron 29 (6930+5ArG), leading to the
skipping of exon 29, a partial reduction of collagen VI in muscle biopsy, and an intermediate phenotype. In family
II, the patient had an unusual mild phenotype, despite a nonsense mutation, R465X, in exon 5. Analysis of the
patient’s COL6A3 transcripts showed the presence of various mRNA species—one of which lacked several exons,
including the exon containing the nonsense mutation. The deleted splice variant encodes collagen molecules that
have a shorter N-terminal domain but that may assemble with other chains and retain a functional role. This could
explain the mild phenotype of the patient who was still ambulant at age 18 years and who showed an unusual
combination of hyperlaxity and finger contractures. In family III, the patient had a nonsense mutation, R2342X,
causing absence of collagen VI in muscle and fibroblasts, and a severe phenotype, as has been described in patients
with UCMD. Mutations in COL6A3 are described in UCMD for the first time and illustrate the wide spectrum
of phenotypes which can be caused by collagen VI deficiency.
Introduction
Congenital muscular dystrophies (CMDs) constitute a
group of disorders characterized by early-onsetmuscular
weakness and joint contractures, as well as dystrophic
features identified by the morphological analysis of skel-
etal muscle. A subgroup of CMDs with merosin defi-
ciency displays a fairly uniform clinical phenotype, usu-
ally including severe muscular weakness and always
associated with brain white-matter changes. Patients
with CMD who did not have merosin deficiency (i.e.,
who had merosin-positive CMDs) constitute a hetero-
geneous group showing a broad clinical spectrum with
variations in distribution of the muscle involvement, de-
gree of severity, progression, and other accompanying
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features (Voit 2001). A peculiar form of CMD was first
reported, under the name of “congenital atonic-sclerotic
muscular dystrophy,” by Otto Ullrich in 1930, in two
boys presenting with an unusual combination of marked
distal joint looseness (atonic) and contracture of prox-
imal joints (sclerotic), with generalized muscle wasting
and weakness since birth (CMD) and normal intelligence
(Ullrich 1930). Other cases sharing a similar clinical pic-
ture confirmed the existence of this condition, whichwas
named “Ullrich disease” (see Nonaka et al. 1981; Voit
1998). An autosomal recessive mode of inheritance was
determined in familial cases of the disease (Nonaka et al.
1981). The progression of muscle involvement is slow,
and the severity of this condition varies from mild to
severe, with loss of walking (Ricci et al. 1988; De Paillette
et al. 1989).
The involvement of extracellular matrix proteins in
the pathogenesis of CMD was first suggested by differ-
ent authors and later was demonstrated immunologi-
cally and genetically (Tome´ 1999). Mutations in the
laminin a2 chain (merosin), one of the three chains
forming laminin-2 and laminin-4, a major component
of the extracellular matrix, cause merosin-deficient
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Figure 1 Pedigrees of three families with CMD, with distal hyperlaxity, showing linkage to chromosome 2q37. Disease-bearing haplotypes
are boxed for each family. Affected individuals are represented by blackened symbols, heterozygous carriers of the disease haplotype by half-
blackened symbols, and unaffected noncarrier individuals by unblackened symbols. The order of the markers was obtained from the databases
of the Whitehead Institute/MIT Center for Genome Research, the National Center for Biotechnology Information (Genemap 99), and the
Marshfield Center for Medical Genetics. HCOLINT is a COL6A3 intronic CA-repeat microsatellite (Pan et al. 1998b).
CMD (Helbling-Leclerc et al. 1995). Recently, after an
initial report on collagen VI deficiency in the muscle-
biopsy samples of two Japanese patients with Ullrich
disease (Higuchi et al. 2001b), mutations of COL6A2,
the gene encoding the a2 chain of collagen VI, were
identified in three Italian patients and one Japanese pa-
tient with the disease known as “Ullrich scleroatonic
muscular dystrophy” or Ullrich CMD (UCMD [MIM
254090]) (Camecho Vanegas et al. 2001; Higuchi et al.
2001a). Mutations in this gene (Jo¨bsis et al. 1996), as
well as in COL6A1 and COL6A3 (encoding the a1 and
a3 chains of collagen VI), cause an autosomal dominant
disorder, Bethlem myopathy (MIM 158810) (Pepe et al.
1999a; Sasaki et al. 2000).
By genomewide analysis, we studied a consanguine-
ous family in which three patients had merosin-positive
CMD and distal hyperlaxity, and wemapped the disease
to a locus in 2q37 by homozygosity mapping. Linkage
was confirmed in two other consanguineous families,
with a maximum LOD score of 4.28 at a recombination
fraction of v p 0.00. We analyzed a candidate gene
located in the region, COL6A3, and identified three ho-
mozygous mutations (two nonsense mutations and a
splice-site mutation) in these three families.
Patients and Methods
Patients
We studied 5 patients and 11 unaffected relatives from
three consanguineous families in which CMD was as-
sociated with distal laxity (fig. 1). They provided written
informed consent to participate in our study. CMD di-
agnosis was based on the EuropeanNeuromuscularCen-
ter workshop consensus criteria: onset of symptoms at
birth, diffuse muscle weakness, proximal contractures,
and muscle-biopsy samples showing fibers of variable
size and an increase in endo- and perimysial connective
tissue (Dubowitz 1997). Immunocytochemically, the ex-
pression of laminin a2 chain and dystrophin-associated
glycoproteins was normal. Family I (patients 1–3) orig-
inated from Morocco, family II (patient 4) from Italy,
and family III (patient 5) from Turkey. The parents in
each of the three families were first cousins.
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Genotyping
Genomic DNA was extracted from peripheral lym-
phocytes by standard procedures. Linkage to known
CMD loci (LAMA2, RSMD1, MEB, and MDC1B) was
excluded by genotypic analysis of polymorphic markers
(Guicheney et al. 1998; Cormand et al. 1999; Moghad-
aszadeh et al. 1999; Brockington et al. 2000). We per-
formed a whole-genome linkage analysis of 280 micro-
satellite markers, as described elsewhere (Vicart et al.
1998). Additional polymorphic markers were used for
fine mapping of potential loci. Forward primers were
labeled with 6-Fam, Hex, or Ned fluorochromes. The
fluorescent PCR products were separated and detected
on 4.25% acrylamide gels with an ABI 377 DNA se-
quencer, and alleles were assigned with Genotyper soft-
ware version 2.5 (Applied Biosystems).
Skin Fibroblasts
Primary fibroblasts were grown from skin-biopsy sam-
ples of patients 4 and 5. Before RNA extraction, con-
fluent cells were treated with 100 mg/ml cycloheximide
(Sigma) for 8 h, as described elsewhere (Lamande´ et al.
1998a).
RNA Extraction and RT-PCR
Total RNA was extracted from fibroblasts or muscle-
biopsy samples by use of RNA-PLUS extraction solution
(Q.Biogen). We performed reverse transcription with
OligodT for fibroblast RNA and with random hexamers
for muscle RNA, using the Superscript kit (Life Tech-
nologies). The resulting cDNA was used as a template
for PCR with the 15 primer pairs designed by Pan et al.
(1998a). RT-PCR products were analyzed by electro-
phoresis on 2% agarose gel.
Sequencing
RT-PCR products were sequenced on both strands by
use of an Applied Biosystems automated sequencer (Per-
kin Elmer). Sequence changes identified at cDNA level
were confirmed on genomic DNA by amplification and
direct sequencing of the specific exons. We designed new
primers: for exon 5, 5F (5′-GAAGTCAACAAGAGAGA-
CATA-3′) and 5R (5′-TAGAGCAGAGCCCGTGTA-3′);
for exon 29, 29F (5′-CAGCGGCAGGGCAGAGAC-3′)
and 29R (5′-TCATCAAACGAAAACACTCACTCAA-
3′); and, for exon 31, 31F (5′-TTACCCCACGGACCC-
TCA-34) and 31R (5′-CAAAGCCTCAGCAGTTAATC-
ACA-3′). The sequences of F1 and B5 primers are
5′-TCCTACAACTCATGCCCAGC-3′ and 5′-GTCAGA-
TGACCTTCCTGCGACC-3′, respectively.
SSCP Analysis
SSCP analysis was performed as described elsewhere
(Di Blasi et al. 2001). A silver-staining kit (Promega,
Silver Sequence, DNA staining reagents) was used to
visualize the DNA bands on the gels.
Restriction Analysis
We digested PCR fragments of exon 29 (5 ml) for 1.5
h at 37C in a final volume of 15 ml with MaeII (1 U,
Biolabs) and visualized digested fragments on 2% aga-
rose gels.
Immunohistochemistry
Unfixed frozen sections of muscle tissue from patients
and from controls were double labeled with anti-collagen
VI antibody (MAB1944 orMAB3303, Chemicon) diluted
1/200, and rat anti-perlecan (Chemicon) diluted 1/100,
followed by fluorescein isothiocyanate (FITC)–conjuga-
ted anti-mouse (DAKO), and tetramethylrhodamine iso-
thiocyanate–conjugated anti-rat (Sigma). Other extra-
cellular-matrix proteins, such as laminin a2 chain (Chem-
icon), laminin b1 chain (Chemicon), collagen IV (Sigma),
and fibronectin (Sigma) were studied to evaluate the in-
tegrity of basal lamina. Primary antibodies were diluted
1/1,000, 1/100, 1/50, and 1/400, respectively, and were
revealed with anti-mouse or anti-rabbit FITC-conjugated
secondary antibodies (DAKO). All samplesweremounted
in Pro-long anti-fade reagent (Molecular Probes) andwere
observed with a Nikon E 600 fluorescence microscope.
Cultured skin fibroblasts from patients and controls
were grown to confluence on coverslips and were treated
with 0.25 mM ascorbic acid for 5 d, to allow collagen
molecules to be hydroxylated and secreted (Chan et al.
1990). Samples were fixed with cold methanol at20C
for 7 min, were incubated for 1 h at room temperature
with anti-collagen VI monoclonal antibodies (MAB3303
and MAB1944, Chemicon) diluted 1/100 with PBS con-
taining 2% BSA and 5% normal goat serum, as well as
with FITC-conjugated rabbit anti-mouse antibody
(Dako) diluted 1/100. The slides were stained with
1mg/ml 4′,6′-diamidino-2-phenylinodole hydrochloride
(DAPI).
Linkage Analysis
Linkage analysis was performed by use of the LINK-
AGE 5.2 package, under the assumptions of an auto-
somal recessive inheritance, an equal male and female
recombination rate, a disease-gene frequency of 0.0001,
and a penetrance of 0.95. LOD scores were calculated
with allele frequencies determined in a control popula-
tion of European origin.
Results
Identification of a New CMD Locus
Two hundred eighty microsatellite markers were ge-
notyped in a consanguineous family with merosin-
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Table 1
Cumulative Two-Point LOD scores for UCMD versus Chromosome
2q37
MARKER
LOD SCORES AT v p
.00 .01 .05 .1 .2 .3 .4
D2S336 .37 1.48 1.82 1.70 1.16 .57 .12
GATA5HO2 3.13 3.05 2.73 2.34 1.58 .90 .36
D2S2202 3.29 3.21 2.87 2.44 1.63 .92 .37
D2S345 4.00 3.90 3.53 3.06 2.13 1.25 .51
HCOLINT 4.00 3.90 3.53 3.06 2.13 1.25 .51
D2S338 4.28 4.17 3.76 3.24 2.23 1.29 .52
D2S1359 3.57 3.48 3.10 2.62 1.72 .95 .37
D2S2968 2.68 2.62 2.34 2.00 1.34 .76 .30
D2S2253 2.29 1.21 1.59 1.50 1.04 .55 .18
D2S2338 2.68 2.62 2.34 2.00 1.34 .76 .30
Figure 2 The 18-year-old patient (patient 4) shows the unusual
combination of striking distal contractures and hyperlaxity. When the
wrist is extended, the retraction of finger flexor muscles impedes a
complete finger extension, causing the flexion contractures of the fin-
gers, which is regarded as a characteristic “Bethlem” sign. When the
wrist is not extended, the finger laxity becomes evident. The patient
is able to overlap, cross, or extend fingers beyond the normal range
of motion (“Ullrich” sign).
positive CMD, comprising three affected and one un-
affected siblings (family I). Seven markers were found
to be homozygous in the three affected siblings (patients
1–3). Four of these regions were excluded after analysis
of flanking microsatellite markers; the remaining three
corresponded to potential loci on 2q34-35, 2q37, and
14q24. We analyzed the markers corresponding to these
three loci in other consanguineous merosin-positive fam-
ilies with CMD who had normal intellectual develop-
ment and brain MRI. We found two additional families
with linkage to the potential locus on chromosome 2q37
(fig. 1).
The patients of the three families presented some sim-
ilar phenotypic characteristics, especially joint contrac-
tures coexisting with distal laxity. Two recombination
events between D2S336 and GATA5HO2 and between
D2S2968 and D2S2253 in patient 3 defined a 13-cM
interval, according to the Marshfield chromosome 2 sex-
averaged linkage map (Broman et al. 1998), containing
a candidate gene, COL6A3, which encodes the a3 chain
of collagen VI (fig. 1). Six markers gave significant pos-
itive cumulative LOD scores, the highest ones being
4.28, for D2S338, and 4.00, for HCOLINT and
D2S345, at (table 1). As expected, given thevp 0.00
autosomal recessive mode of transmission, all the af-
fected individuals had the two at-risk haplotypes,
whereas three unaffected siblings from families II and
III had inherited one at-risk haplotype (fig. 1).
Phenotypic Features
The patients from the three families shared significant
clinical features (table 2), consistent with what is gen-
erally referred to as Ullrich disease. Neonatal hypotonia,
severe in most cases, was the presenting sign in all pa-
tients; in spite of it, no respiratory or feeding problems
were ever noticed. Distal hyperlaxity, involving hands
and feet, was also present in every case from birth, as-
sociated with congenital arthrogryposis in families I and
III. Abnormal motor development was constant, ranging
from inability to run in patient 4 (the less-severely in-
volved patient) to failure to acquire gait in patient 5; the
two eldest siblings in family I were never able to walk
without support (calipers or walking frame). General-
ized muscle weakness, associated with predominantly
distal amyotrophy, became evident in the first years of
life. The axial muscles (mainly neck flexors), the pelvic
girdle muscles, and the intrinsic muscles in hands and
feet were the most severely affected ones, scoring ∼2/5
(MRC scale). Lower limbs tended to be more severely
affected than upper limbs; in most cases, hip extensors
and abductors were weaker than hip flexors, leading to
hip contractures that interfered with standing position.
No significant facial weakness was observed. CK levels
were normal or moderately raised (up to four times the
normal values).
Muscle weakness appeared almost stable in all cases.
In the families presenting with congenital arthrogry-
posis, contractures improved or even disappeared (pa-
tient 3) with intense physiotherapy during the first years
of life. However, from the age of 8–12 years, contrac-
tures evolved and became severe in proximal joints, es-
pecially in lower limbs. Ankle and feet hyperlaxity was
replaced by ankle contractures and/or equino-varus feet,
requiring surgical correction in patient 4 and eventually
leading to loss of ambulation in patients 1 and 2, at 15
and 14 years of age, respectively. Finger retractions were
noticed only in patient 4, from the age of 13 years (fig.
2). Only patient 5 developed scoliosis and kyphosis.
Heart-function tests (electrocardiogram and echocar-
diography) and brain MRI were performed in at least
one patient per family and did not show any abnor-
mality. There was no clear mental retardation in any
case, although school performance was poor in patients
1, 4, and 5. No ocular abnormalities were observed.
Examination of other family members, including par-
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Table 2
Clinical Features of the Patients
CHARACTERISTIC
FEATURE IN PATIENT
1 2 3 4 5
Present age (years) 17 15 3 18 12
Neonatal hypotonia Present Present Present Present Present
Congenital arthrogryposis Present Present Present  Present
Congenital hip dislocation     Present
Congenital torticollis Present    Present
Delayed motor milestones Present Present Present  Present
Age at walking (mo) 36 24 26 13 Never
Maximal motor capacity Walking with support Walking with support Walking Walking Stepping for a
short distance
Weakness:
Facial muscles     
Shoulder girdle     
Pelvic girdle     
Feet and hands     
Neck flexors     
Contractures:
Spine extensors  /  
Knees     
Hips    (transient)  
Fingers    (transient)  
Ankles     
Distal hyperlaxity     
Scoliosis     
Kyphosis   Transient  
Creatine kinase 3# normal (5 d);
normal (11 mo)
Normal Normal 4# normal (13 years) Normal
Clinical course Improving at age
0–12 years; slowly
progressive at age
112 years
Improving at age 0–8
years; slowly pro-
gressive at age 18
years
Improving Static Slowly progressive
Intelligence Normal Normal Normal Borderline Normal
Collagen VI Reduced Reduced 
Perlecan Normal Normal Normal
NOTE.— p absent;  p mild;  p moderate;  p severe.
ents, showed no abnormality except for the youngest
heterozygous sib of family III, who showed, at birth, a
marked hyperlaxity of hands and feet without muscle
weakness. Her early motor and mental development was
normal at 1.5 years of age, and hyperlaxity tended to
decrease.
Immunohistochemistry of Collagen VI
Muscle-biopsy samples (from one patient per family)
were analyzed for the presence of collagen VI. Results
obtained with MAB3303 and MAB1944 were identical.
For patients 1 and 4, a mild reduction in collagen VI
was observed in the endomysium; however, in the areas
showing marked collagen increase, the perimysium and
endomysium labeling appeared to be similar to that of
controls (fig. 3A–C). In contrast, for patient 5, no im-
munostaining of collagen VI could be detected (fig. 3D).
Labeling with antibody against perlecan showed a nor-
mal pattern in all cases examined (fig. 3E–H), as did
labeling with antibodies against collagen IV, laminin a2
chain, and fibronectin (data not shown). Laminin b1
chain was moderately reduced in the basal lamina of
muscle fibers of patient 4 and was normally expressed
in the muscle of patients 1 and 5 (data not shown).
Abnormality of collagen VI was confirmed in patients
4 and 5 by the study of cultured skin fibroblasts (fig.
4). Cultured fibroblasts from patient 4 presented a re-
duced amount of secreted protein, with a dot-like ap-
pearance, when compared with the fine network of the
collagen VI deposited by control fibroblasts (fig. 4A and
B). Collagen VI was absent in cultured fibroblasts from
patient 5, both inside the cells and in the extracellular-
matrix (fig. 4C). DAPI staining of the nuclei demon-
strated that patients and control fibroblasts had a com-
parable cell density.
COL6A3 Genomic Sequence
On the basis of the sequences of COL6A3 mRNA
(X52022) and several PAC clones (AC025878,
AC025933, and AC0259332), we identified and num-
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Figure 3 Double labeling of collagen VI with MAB1944 (A, B,
C, and D) and perlecan (E, F, G, and H) in muscle-biopsy samples.
Collagen VI is strongly expressed at the basal lamina of muscle fibers
and around the vessel in a control subject (A) but appears reduced in
patients 1 (B) and 4 (C) and absent in patient 5 (D). Same sections
were labeled with anti-perlecan antibody to check the integrity of basal
lamina. The labeling was comparable in all samples examined. E, F,
G, and H, normal muscle and muscle from patients 1, 4, and 5 re-
spectively (of families I, II, and III, respectively). Bar p 100 mm.
Figure 4 Immunofluorescence analysis of collagen VIMAB1944
(A, B, and C) and DAPI (D, E, and F) in cultured fibroblasts. Collagen
VI in the control subject (A) is highly expressed in the extracellular
matrix and develops a fine network. The protein is reduced in amount
and is not well organized in fibroblasts of patient 4 (B), whereas it is
absent in fibroblasts of patient 5 (C). The DAPI staining shows a
comparable density of cells in the three samples: normal control (D),
patient 4 (E), and patient 5 (F). Bar p 100 mm.
bered the first 40 COL6A3 exons (fig. 5). The coding
sequence begins in exon 2 (ATG), which corresponds to
the exon 11 previously defined by Stokes et al. (1991).
N-terminal domains, named “N10” to “N2” (Stokes et
al. 1991) correspond to exons 3–11, whereas the N1
domain is encoded by exons 12–14 and the triple-helical
domain is encoded by exons 15–33.
Mutation Analysis
In patient 1 from family I, analysis of muscle mRNA
by RT-PCR showed a shorter product for one of the
COL6A3 PCR products than was seen in control sub-
jects. Sequence analysis revealed a 51-bp deletion, cor-
responding to the skipping of exon 29 (fig. 6A). Sequence
analysis of this exon with intronic primers revealed a
homozygous GrA transversion at the5 position in the
donor-splice site of intron 29, 69305GrA. This mu-
tation should induce a homozygous in-frame deletion of
17 amino acids in the triple-helical domain of the a3
chain of collagen VI. The mutation abolishes a MaeII
restriction site. Since we could not detect the mutation
by PCR-SSCP analysis, we amplified DNA from family
members and from 50 unrelated Moroccan control sub-
jects and digested the PCR products by MaeII. No con-
trol subject carried the mutation, but the two parents
were heterozygous carriers (fig. 6A). These data strongly
suggest that this mutation is not a DNA polymorphism,
but a splicing mutation leading to the disease.
In family II, a homozygous CrT transition was found
at position 1393 in the COL6A3 coding sequence,
changing an arginine 465 (CGA) to the stop codon TGA.
This 465RrX nonsense mutation was predicted to cause
a small truncated protein with only the two first N-
terminal domains. This mutation was detected in patient
fibroblast and muscle cDNA, as well as in genomic DNA
in exon 5. It was transmitted by the parents and was
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Figure 5 Localization of the three mutations. Schematic representation of the 41 first exons COL6A3 cDNA with the corresponding
structural domains, as defined by Chu et al. (1990). The primers F1 and B5 are shown (arrows). The three hatched exons (4, 6, and 7) has
been reported elsewhere to be spliced in human muscle and fibroblasts.
Figure 6 Mutation analysis in families I, II, and III. A, Family I. RT-PCR amplification of the coding a3 triple-helical domain of COL6A3
with primers COL6A3-1 and COL6A3-2 showed a smaller fragment, corresponding to a deletion of 51 bp in patient muscle cDNA, compared
with control muscle cDNA; this deletion was due to the skipping of exon 29, as is shown by control and patient cDNA sequences (right panel).
At the genomic level, an homozygous 69305GrA was found in the donor splice site of intron 29 (middle panel). The mutation cosegregated
with the disease in the family, as is shown by RFLP analysis. The 6930GrA substitution abolishes a MaeII site in a 264-bp PCR fragment of
exon 29. One band, corresponding to two fragments (130 and 134 bp), was found in control subjects and in the oldest unaffected sibling,
whereas one uncut fragment (264 bp) indicated the homozygous mutated alleles. Parents were carriers of a mutant and a normal allele (left
panel). B, Family II. Electrophoregram sections showing a homozygous CrT transversion at nucleotide 1393, changing Arg465 (CGA) to a
stop codon (TGA) (middle panel). Segregation of the mutation in family II by SSCP analysis (left panel). RT-PCR amplification of patient 5
and control fibroblast and muscle cDNA samples encompassing exons 2–7 of COL6A3, by use of primers F1–B5, showed two main products:
one of 980 bp, corresponding to exons 2, 5, and 7, and a smaller one of 395 bp, corresponding to exons 2 and 7. The shorter band was much
more abundant in fibroblast and muscle cDNA from patient 5 than in that from control subjects (right panel). Segregation of the mutation in
family II, by SSCP analysis, showing abnormal conformers in the homozygous patient and in the three heterozygous family members compared
with control subjects (left panel). C, Family III. Electrophoregram sections showing a homozygous CrT transversion at nucleotide 7024 creating
a stop codon (right panel). Segregation of the mutation in family III by SSCP analysis showing abnormal conformers in the homozygous patient
and in the four heterozygous family members compared with control subjects (left panel).
not found in 100 unrelated Italian control subjects by
SSCP analysis (fig. 6B). Since the patient presented only
a partial deficiency in collagen VI, a skipping of exon
5, which consists of a multiple of 3 (585 bp), could
explain the mild phenotype. As shown in figure 6B, dif-
ferent patterns were observed in patient and control
cDNA amplified by F1-B5. In control fibroblasts and
control muscle, a main band of 980 bp comprises exons
2, 5, and 7. In contrast, the main band in patient fibro-
blasts was of 395 bp and comprised only exons 2 and
7, suggesting the skipping of exons 3, 4, 5, and 6. This
band was also clearly detected by PCR in cDNA from
patient muscle.
In family III, we identified a homozygous CrT tran-
sition at position 7024 in exon 31 encoding the alpha
triple-helical domain. It changed codon 2342, coding for
an arginine (CGA), to a stop codon, TGA, which should
result in a truncated protein lacking the whole C-terminal
domain. This mutation in exon 31 was not detected in
100 unrelated Turkish control subjects by SSCP analysis
(fig. 6C).
Discussion
We identified a locus on chromosome 2q37 in three fam-
ilies with merosin-positive CMD with distal hyperlaxity.
In this locus, COL6A3, the gene encoding the a3 chain
of collagen VI, was a candidate gene for this condition,
since a partial or a complete deficiency in collagen VI
was found in the muscle-biopsy samples of patients from
these families. In addition, one of our patients (patient
4) had both distal hyperlaxity and finger contractures,
the latter of which is known to be a typical feature of
Bethlem myopathy (Merlini et al. 1994), which is caused
by mutations in the three chains of collagen VI (Jo¨bsis
et al. 1996). Reports concerning the identification of
collagen VI deficiency (Higuchi et al. 2001b) and ho-
mozygous mutations of COL6A2 in Ullrich’s disease
(Camecho Vanegas et al. 2001; Higuchi et al. 2001a)
strengthened that possibility. As a result, we screened
COL6A3 coding sequence and identified homozygous
mutations.
Collagen VI is a major cell-adhesive protein that forms
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a microfibrillar network in the extracellular matrices of
a wide variety of tissues, including skeletal muscle, skin,
and cartilage (Keene et al. 1988; Bonaldo et al. 1998).
Collagen VI is composed of three different polypeptide
chains (a1, a2, and a3) assembled intracellularly to form
triple-helical monomers (Timpl and Chu 1994). Mono-
mers further associate into dimers by antiparallel over-
lapping alignment, and subsequently associate into tet-
ramers by lateral association (Furthmayr et al. 1983;
Odermatt et al. 1983; Chu et al. 1988). These molecules
are stabilized by disulfide bonds. Multimer assembly is
essential for secretion and the formation of stable col-
lagen monomers (Lamande´ et al. 1998b). All three chains
comprise a central triple-helical domain of 335 or 336
amino acids with repeating Gly-X-Y sequences, flanked
by N-and C-terminal globular domains (Timpl and Chu
1994). The N globular domain is composed of ∼200
consecutive amino acid–residue repeats, each of which
forms a globular subdomain. The a3 chain is the largest,
with 10 residue motifs (N10–N1), whereas, in both a1
and a2 chains, only one (N1) exists. The subdomains in
N and C-terminal regions show homology to the type A
domains of the von Willebrand factor, fibronectin type
III domains, and Kunitz-type protein inhibitors (Bonaldo
and Colombatti 1989; Chu et al. 1990).
In our series, three children from family I were hy-
potonic at birth, and one of them presented with ar-
throgryposis multiplex congenita. Clinical status im-
proved, and they achieved ambulation but had difficulties
running and climbing stairs, because of weakness and
contractures, as generally occurs in patients with CMD.
A distal hyperlaxity of the hands, feet, and arms was
noticed early in all three children. No finger contracture
was detected. In this family, we found a homozygous
deletion of 51 nucleotides at the transcript level by anal-
ysis of the muscle specimen from one of the affected
children. A homozygous point mutation in the donor
splice site of COL6A3 intron 29, identified in the three
affected children, resulted in skipping of exon 29 and in-
frame deletion of 17 amino acids in the triple helical
domain. In 85% of the primate genes, a G is found in
the donor site at 5 position, and, if an A or T change
occurs, it generally induces skipping of the exon (Nakai
and Sakamoto 1994). This is what we observed, even if
a very small amount of primary transcript with the mu-
tation undergoes correct splicing. No specific function
has been assigned to the deleted region. It does not in-
clude cysteine residue and does not affect multimeric as-
sembly and secretion. Expression of partially functional
proteins due to in-frame deletions has also been reported
to cause mild phenotypes in patients with merosin-neg-
ative CMD (Allamand et al. 1997; Di Blasi et al. 2001).
In families II and III, we identified two homozygous
nonsense mutations having very different functional and
pathophysiological consequences. In family II, the pa-
tient presented with the mildest phenotype of the five
patients reported in this article. At the age of 18 years,
he was still ambulant but had some contractures. He
had the rare association of marked distal hyperlaxity
and finger contractures, as is shown in figure 2. In this
patient, we identified a nonsense mutation in the exon
5 coding N8 globular domain of a3 chain. Although
the transition of an arginine residue to a stop codon
was predicted to truncate 2,712 amino acids, the im-
munohistochemical analysis of bothmuscle-biopsy sam-
ples and fibroblasts showed only slightly reduced col-
lagen VI expression. The mild clinical phenotype of the
patient was also inconsistent with the presence of a non-
sense mutation. It has been shown that common alter-
native splicing or aberrant splicing induced by a non-
sense mutation could moderate the consequence of the
nonsense mutation by skipping of the exon (Valentine
1998). Alternative splicing of exons 3, 4, 6, and 7 of
COL6A3 have been reported in various human tissues,
including skeletal muscle and fibroblasts from healthy
individuals (Stokes et al. 1991; Zanussi et al. 1992). In
constrast, splicing of exon 5 had not been observed
before in human tissue. We showed splicing of exons
3, 4, 5, and 6 in the fibroblast and muscle of both the
patients and the control subjects (fig. 6B). Because re-
moval of the exons did not cause a frameshift in the
coding sequence, the alternatively spliced mRNA may
produce a functional protein. In an expression study,
an a3 chain cDNA construct lacking domains N10–N7
was shown to assemble and incorporate into the extra-
cellular matrix (Lamande´ et al. 1998b). The mainte-
nance of this functional collagen VI isoform may ex-
plain the mild phenotype in the patient and the absence
of clinical signs in the heterozygous carriers.
Patient 4 (family III), who presented with the most
severe phenotype, had a nonsense mutation in exon 31
coding for the distal part of the triple helical domain.
The protein could not be detected by immunocyto-
chemical analysis of muscle biopsy and fibroblasts, ei-
ther in the intracellular or extracellular compartment
(fig. 3). The truncated part included the C-terminal
globular domain, which interacts with the triple-helical
domain of another monomer in the stabilization of col-
lagen VI dimers. Expression of the a3 chain is essential
for the formation of functional collagen VI molecules
and their secretion (Chu et al. 1988; Lamande´ et al.
1998b). When the a3 chain is absent, a1 and a2 chains
cannot form helical assemblies and are unstable. The
absence of immunostaining with the two monoclonal
antibodies directed against the a3 chain could be due
to the truncation of the epitope or/and more probably
to the instability of the RNA or the synthesized trun-
cated collagen VI, as shown elsewhere (Lamande´ et al.
1999). The parents were both heterozygous carriers of
the nonsense mutation, but they did not present any
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symptoms. A marked distal laxity was noticed at ex-
amination in their youngest child, also a heterozygous
carrier, but he did not develop weakness or hypotonia.
Our patients constituted a relatively homogeneous
clinical group on the basis of themain features—namely,
early onset of the disease, distal hyperlaxity, proximal
contractures, and marked involvement of flexor neck
muscles. However, the severity of the disease varied. We
observed the most severe phenotype in the patient from
family III with no collagen expression. Indeed, a high
proportion of patients with typical Ullrich disease never
walk or become ambulant but lose gait after some years
(Nonaka et al. 1981). Among the reported patients with
a known mutation leading to an absence of collagen
VI, one of the main features was the development of a
marked respiratory insufficiency, leading to tracheot-
omy in the four oldest patients, at the ages of 7, 8, 14,
and 17 years, respectively (Camecho Vanegas et al.
2001; Higuchi et al. 2001a). In contrast, our patients
with mildly reduced collagen VI expression presented
with a milder phenotype and no respiratory insuffi-
ciency, suggesting a correlation between the degree of
collagen VI reduction and the severity of the disease.
The existence of mutations leading to protein deficiency
supported such correlation. However, the phenotypical
consequence of mutations in the COL6A3 gene may be
modulated by the functional properties of collagen VI
or by alternative splicing. Mutations interacting with
intracellular assembly may interrupt secretion of col-
lagen VI, leading to functional haploinsufficiency of col-
lagen VI in the extracellular matrix (Lamande´ et al.
1999). On the other hand, aberrant exon skipping may
suppress the effect of mutation, as is seen in the patient
from family II.
It is noteworthy that none of the heterozygous car-
riers of a UCMD-causing mutation in COL6A3 or
COL6A2 was affected or even presented with weakness
at adulthood. In contrast, in Bethlem myopathy, het-
erozygous carriers of mutations in any of the genes en-
coding an a chain, develop an early-onset, slowly pro-
gressive limb-girdle weakness with contractures. The
mutations so far identified in Bethlem myopathy and
UCMD are different. In Bethlem myopathy, seven dif-
ferent mutations were reported. Four are missense mu-
tations: three of them are glycine substitutions within
the triple-helical domain of one of the three chains that
interrupt the collagen Gly-X-Y amino acid repeat se-
quence (Jo¨bsis et al. 1996; Pepe et al. 1999a), whereas
the other one leads to a glycine-to-glutamic-acid change
within the N2 repeat of the a3 chain (Pan et al. 1998a).
Two other mutations are splice-site mutations in
COL6A1 inducing an in-frame deletion of 18 amino
acids in triple helical domain of the a1 chain (Lamande´
et al. 1999; Pepe et al. 1999b). Finally, anothermutation
was reported to induce a 1-bp deletion (9791GrA)
and a premature termination of the protein (Lamande´
et al. 1998a). It is noteworthy that the phenotype as-
sociated with this latter mutation in COL6A1 is at var-
iance with the phenotype of the heterozygous carriers
of a COL6A2 or COL6A3 UCMD mutation leading to
premature termination codon, who are all healthy.
In Bethlem myopathy, like in other collagenopathies,
mutant chains may assemble with normal chains, dis-
rupting the stability of the monomers, dimers, or tet-
ramers, and may lead to increased intracellular degra-
dation and poor collagen secretion. In relation to the
mutation, a proportion of mutant molecules could not
be degraded but were secreted and incorporated into
the extracellular matrix, where the presence of even a
small number of abnormal molecules can exert a dom-
inant negative effect, thus disturbing the entire matrix
architecture and no longer adequately anchoring the
muscle cell to the surrounding connective tissue. It is
now known that, in most patients with Bethlem my-
opathy, no reduction in collagen VI can be detected in
muscle-biopsy samples, which suggests that the mech-
anisms are multiple and are more complex than a hap-
loinsufficiency of collagen VI, as has been suggested for
one patient (Lamande´ et al. 1998a).
The mechanisms causing the dystrophic changes in
Ullrich congenital muscular dystrophy are still specu-
lative, although the major role of collagen VI is proven.
Extracellular matrix has been shown to be essential for
the formation of myotubes and expression of later mus-
cle-specific gene products during skeletal-muscle-cell
differentiation (Melo et al. 1996). Collagen VI differs
from other members of the large family of collagens by
its unique crosslinking properties; it interacts with nu-
merous extracellular matrix components (Kuo et al.
1997; Tillet et al. 1997)—such as collagen IV, perlecan,
fibronectin, and fibrillar collagen I/III—that are indi-
rectly linked to the cell surface. Expression of collagen
IV, perlecan, and fibronectin was normal in all the mus-
cle-biopsy samples that we studied. Laminins were also
normally expressed, except for the laminin b1 chain,
which appeared moderately reduced only in the muscle
fibers of the oldest patient (patient 4); a similar age-
related alteration has been previously reported in three
patients affected by Bethlem myopathy (Merlini et al.
1999). However, a reduced expression of laminin b1
cannot be considered specific to collagen VI-related pa-
thologies, since it has been described in other muscle
diseases (Yamada et al. 1995).
On the other hand, it has been recently demonstrated
that absence of collagen VI modifies the fibronectin net-
work architecture in fibroblast cultures (Sabatelli et al.
2001) andmarkedly reduces cell proliferation (Atkinson
et al. 1996). In addition, collagen VI prevents apoptosis
in serum-starved fibroblasts, possibly through activa-
tion of tyrosine phosphorylation of focal adhesion pro-
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teins, such as FAK (Ruhl et al. 1999). These complex
mechanisms affecting differentiation, regeneration, and
apoptosis may also apply in muscle andmay be involved
in the pathological pathways caused by collagen VI
deficiency.
The functional effect of the two mutations causing a
partial collagen VI deficiency might be related to dis-
ruption of specific interactions. Indeed, most proteins
interact with collagen VI through its helical domain.
The deletion found in the distal part of the helix, in-
duced by 69305GrA, may thus affect some of these
specific interactions. In contrast, the R465X mutation,
which induces an in-frame deletion in the N-terminal
globular domain, should not disturb interactions with
the helical domain, but might abolish the specific in-
teraction of terminal N9-N2 domains with heparin and
hyaluronic acid (Specks et al. 1992).
In conclusion, in this study, we report the first ho-
mozygous mutations in COL6A3 leading to complete
or partial collagen VI deficiency associated with severe
or milder phenotypes of UCMD. These results suggest
that a significant proportion of patients with still-un-
classified merosine-positive CMD—particularly if they
show distal hyperlaxity—may present a partial defi-
ciency in collagen VI. Immunocytochemical analysis of
muscle-biopsy samples or skin fibroblasts and identifi-
cation of the genetic defects should allow a better un-
derstanding of these diseases.
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